NEW YORK--(BUSINESS WIRE)--Neurogene Inc., a company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, today announced the appointment of Christine Mikail as President. Ms. Mikail has nearly two decades of experience working in the biotechnology and pharmaceutical industries through various positions in legal, business development, operations and finance capacities. Most recently, she co-founded Neumentum, Inc., a neurology specialty pharma company, and Ferndale Advisors, a consulting firm advising small and midsize biotech companies.
“I am delighted to welcome Christine to Neurogene’s leadership team,” commented Rachel McMinn, Ph.D., Neurogene’s Founder and Chief Executive Officer. “She has extensive experience in building innovative biotechs. Christine joins Neurogene at a time of critical growth. I have no doubt she will be an integral leader in our advancement of multiple gene therapy programs toward the clinic.”
During her time at Ferndale Advisors, Ms. Mikail co-founded two start-up companies, led various transformational business development and financing transactions and assisted in raising more than $50 million. Before founding Ferndale Advisors, Ms. Mikail was Chief Administrative Officer and Head of External Business Development/Alliance Management & General Counsel at Axovant Sciences, Inc., where she was an integral member of the team that raised $362 million in the company’s IPO. Prior to joining Axovant, Ms. Mikail held a variety of senior positions at NPS Pharmaceuticals, Inc., Dendreon Corporation, Eli Lilly and Company and ImClone Systems. Ms. Mikail developed her life sciences focus as a corporate and securities lawyer at Reed Smith and WilmerHale. Ms. Mikail graduated cum laude with a B.A. from Rutgers University, Rutgers College, New Brunswick, NJ, and earned a J.D. from Fordham University, School of Law, New York, NY.
“I am thrilled to join the Neurogene team,” said Ms. Mikail. “The passion my colleagues have for accelerating development of new genetic medicines for neurological diseases is clear. I am looking forward to strengthening our operations, as well as our strategic collaborations, to bring potential treatment to patients for whom there are no effective therapies.”
About Neurogene Inc.
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy. For more information, visit www.neurogene.com.